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Abstract
Background: Both deep and profound hypothermia are effectively applied in cardiac surgery of the aortic arch,
when the reduction of cerebral circulation facilitates operations, and for the prevention of ischemic stroke
consequences. Neurochemical discrimination of the effects of deep and profound hypothermia (27 and 17 °C,
respectively) on non-pathological and pathological ischemia-related mechanisms of presynaptic glutamate transport
with its potential contribution to predictive, preventive and personalized medicine (PPPM) was performed.
Methods: Experiments were conducted using nerve terminals isolated from rat cortex (synaptosomes). Glutamate
transport in synaptosomes was analyzed using radiolabel L-[14C]glutamate. Diameter of synaptosomes was assessed
by dynamic light scattering.
Results: Synaptosomal transporter-mediated uptake and tonic release of L-[14C]glutamate (oppositely directed
processes, dynamic balance of which determines the physiological extracellular level of the neurotransmitter)
decreased in a different range in deep/profound hypothermia. As a result, hypothermia-induced changes in
extracellular L-[14C]glutamate are not evident (in one half of animals it increased, and in other it decreased). A
progressive decrease from deep to profound hypothermia was shown for pathological mechanisms of presynaptic
glutamate transport, that is, transporter-mediated L-[14C]glutamate release (*) stimulated by depolarization of the
plasma membrane and (**) during dissipation of the proton gradient of synaptic vesicles by the protonophore
FCCP.
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Conclusions: Therefore, the direction of hypothermia-induced changes in extracellular glutamate is unpredictable
in “healthy” nerve terminals and depends on hypothermia sensitivity of uptake vs. tonic release. In affected nerve
terminals (e.g., in brain regions suffering from a reduction of blood circulation during cardiac surgery, and core and
penumbra zones of the insult), pathological transporter-mediated glutamate release from nerve terminals decreases
with progressive significance from deep to profound hypothermia, thereby underlying its potent neuroprotective
action. So, alterations in extracellular glutamate during hypothermia can be unique for each patient. An extent of a
decrease in pathological glutamate transporter reversal depends on the size of damaged brain zone in each
incident. Therefore, test parameters and clinical criteria of neuromonitoring for the evaluation of individual
hypothermia-induced effects should be developed and delivered in practice in PPPM.
Keywords: Glutamate, Uptake and tonic release, Permanent glutamate turnover, Glutamate transporter reversal,
Deep and profound hypothermia, Neuromonitoring, Individual hypothermia regime, Brain nerve terminals
Background
Hypothermia is effectively practiced in cardiac surgery
to facilitate operations on the aortic arch with the reduc-
tion of cerebral circulation. The optimal degree of
hypothermia for circulatory arrest in aortic arch surgery
has been intensively debated, and the concept of using
hypothermia to diminish the oxygen consumption and
metabolic requirements of hypoxic tissues is rather in-
tuitive [1]. The brain represents only 2–3% of human
body weight; nevertheless, it uses 20–25% of the total
consumption of oxygen and glucose [2]. Postoperative
neurologic morbidity and mortality stay elevated and
concerns over neurocognitive deficits caused by
hypothermic neuronal injury have been raised [1, 3],
despite data of the literature on complete neurocognitive
preservation following deep hypothermic circulatory ar-
rest [4]. Multiple studies using animal models that have
attempted to clarify the optimal temperature for
hypothermic circulatory arrest have generally supported
the use of deeper levels of hypothermia; nevertheless, in-
fluence of a range of temperatures on the brain func-
tioning needs to be better assessed [1]. In general, the
mechanisms of the neuroprotective action of low tem-
peratures during cardio surgery are a topical issue for
medical practitioners.
Ischemic stroke leads to brain impairment and still re-
mains one of the main causes of adult’s disability in de-
veloped countries. In the central core region of the
insult, the neuronal cells are dead within minutes,
whereas in the penumbral zone, the survival of the cells
is probably achievable. Precise monitoring of brain
temperature after stroke, traumatic brain injury, and
subarachnoid hemorrhage is important because the
brain is particularly susceptible and vulnerable to even
small variations in the temperature [5–7]. Therapeutic
hypothermia has long been known to be a nonspecific
and potent neuroprotectant. It was observed in animal
models that hypothermia reduced the size of cerebral in-
farcts by more than a half and this fact was a base for
following clinical trials of therapeutic hypothermia in pa-
tients with ischemic stroke [7, 8]. In human stroke, ad-
ministration of therapeutic hypothermia can improve
short-term survival and neurological recovery and result
in less extensive damage of the brain as it can be seen
on computed tomography scans [9]. Experimental con-
firmation and clinical experience show that therapeutic
hypothermia has a bright prospect for the administration
in acute ischemic brain injury, and the profit is greatest
when the treatment is started earlier, namely, within sev-
eral hours of symptom onset. Low body temperature
should be maintained for a longer period after stroke to
reach long-lasting neuroprotective outcome [9–12]. Al-
though until now, there are no comprehensible standard
parameters of therapeutic hypothermia [13]. Further
identification of hypothermia-sensitive pathological
process can move ahead this perspective approach.
Glutamate is the main excitatory neurotransmitter in
the mammalian central nervous system, which provides
and underlies major aspects of normal brain functioning
[14]. Impaired glutamate homeostasis leads to harmful
neurologic consequences and is a characteristic feature
of pathogenesis of neurological disorders. The extracel-
lular glutamate levels are kept low between exocytotic
events under normal physiological conditions. These
levels are maintained by permanent turnover of the
neurotransmitter via the plasma membrane with an in-
put of tonic release from nerve terminals [15]. The turn-
over is presumably achieved by Na+-dependent high-
affinity glutamate transporters (EAAT types 1-3), which
utilize gradients of Na+ and K+ across the plasma mem-
brane as a driving force. Neurotransmitters are accumu-
lated and stored in synaptic vesicles, the acidic
compartments of nerve terminals, that release their con-
tents by exocytosis upon stimulation. In cerebral hyp-
oxia, ischemia, stroke, and traumatic brain injury, the
development of neurotoxicity is provoked by excesses of
extracellular glutamate in the synaptic cleft released
through glutamate transporter reversal [16].
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Temperature influences the properties of the neuronal
membrane, postpotential synaptic responses, and release
of neurotransmitters (assessed by measuring excitatory
postsynaptic potential), and these temperature-
dependent changes in electrophysiological properties can
result from effects on ion channels of the nerve cells. In
fact, some calcium and voltage-gated sodium channels
are regulated by temperature [7, 17–20]. Using microdi-
alysis, Berger [10] demonstrated that moderate
hypothermia (33 °C) decreased the concentration of am-
bient glutamate, pyruvate, lactate, and glycerol in the
“tissue at risk” area of the infarct but not within the in-
farct core. Low body temperature appears to be associ-
ated with less release of glutamate in humans that is a
marker of ischemia-induced damage of the brain [9].
Many questions are still needed to be answered re-
garding the use of therapeutic hypothermia, the most
important of which is justification of optimal
temperature regime. The aim of this study was the dis-
crimination of the effects of hypothermia on non-
pathological and pathological mechanisms of presynaptic
glutamate transport using rat brain nerve terminals (syn-
aptosomes) and assessment of potential contribution of
these results to predictive, preventive and personalized
medicine (PPPM). In the study: (*) we analyzed com-
paratively the dynamics of permanent glutamate turn-
over between the episodes of exocytosis measuring tonic
release, uptake, and the extracellular level of glutamate
under conditions of deep and profound hypothermia, and
so identified hypothermia-induced changes in ischemia-
unaffected nerve terminals, and (**) we assessed the velocity
of pathological glutamate transporter reversal induced by
membrane depolarization and the application of the proto-
nophore carbonyl cyanide-p-trifluoromethoxyphenyl-hydra-
zon (FCCP) under the same conditions. The latest approach




Wistar rats, males, body weight of 100–120 g, were kept
in the institute in a quiet, temperature-controlled room
at 22–23 °C using special facilities for animals, where
they were provided ad libitum with water and dry food
pellets. The experimental procedures were conducted
according to the Helsinki Declaration “scientific require-
ments and research protocols” and “research ethics
committees.” Experimental protocols were approved by
the Animal Care and Use Committee of the Institute
(protocol from 19/09-2011). Animals were sacrificed by
rapid decapitation [21]. The total number of animals
used in this study was 56, i.e., the assessment of L-
[14C]glutamate uptake - 10 animals; release - 16 animals;
the extracellular level - 30 animals (different parameters
were measured simultaneously using one synaptosome
preparation in several experiments). All experiments
with rats were performed in accordance to the AR-
RIVE guidelines for reporting experiments involving
animals [22, 23].
Isolation of nerve terminals (synaptosomes) from rat
brain
Cerebral hemispheres were quickly isolated and homog-
enized in ice-cold solution containing sucrose (0.32 M),
HEPES-NaOH, pH 7.4 (5 mM), and EDTA (0.2 mM).
One animal was used to obtain one synaptosome prepar-
ation. All procedures were performed at +4 °C. The syn-
aptosome preparations were obtained by differential
centrifugation of rat brain homogenate and then Ficoll-
400 density gradient centrifugation in accordance to
Cotman [24] with minor modifications [25–27]. The ex-
periments using synaptosome preparations can be car-
ried out during 2–4 h after isolation. The standard salt
solution consisted of the following (in mM): NaCl (126);
KCl (5); MgCl2 (2.0); NaH2PO4 (1.0); HEPES, pH 7.4
(20); D-glucose (10); the solution was oxygenated in all
experiments. Ca2+-containing media was supplemented
with CaCl2 (2 mM), whereas Ca
2+-free media did not
contain Ca2+ but was supplemented with EGTA (1 mM).
Concentration of proteins was determined in accordance
to Larson [28].
Treatment of nerve terminals with hypothermia
The synaptosomal suspension obtained as described in
the previous subsection was used for hypothermia exper-
iments. Hypothermia is classified according to [29]
(where deep hypothermia is considered to be from 20 °C
up to 28 °C and profound from 5 °C up to 20 °C). The
measurements were performed both by warming of cold
synaptosomal suspension from 4 °C up to 17, 27, and
37 °C and vice versa by cooling of preliminary warmed
synaptosomal suspension from 37 °C to 27 and 17 °C
(see below uptake and release experiments).
Dynamic light scattering approach
Analysis of the size of synaptosomes under hypothermia
conditions was performed by dynamic light scattering
using a laser correlation spectrometer “ZetaSizer-3” from
Malvern Instrument, UK, equipped with He-Ne laser
LGN-111, P = 25 mW, λ = 633 nm, at scattering angle
90°, and with multi-computing correlator type 7032 ce
synaptosome preparations, sample volume of 1 ml, were
placed in a thermostated cylindrical quartz cuvette, in
which diameter is 10 mm. Synaptosome suspensions
were repetitively measured for 120 s. Processing of ex-
perimental results were performed using computer soft-
ware service PCS-Size mode v1.61.
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Recording of L-[14C]glutamate uptake by nerve terminals
Uptake of L-[14C]glutamate by synaptosome preparations
was measured as follows. Synaptosomes (sample volume
of 125 μl; 0.4 mg of protein per milliliter) were pre-
incubated in the standard salt solution at 37 °C for
8 min (typical experimental approach to restore ionic
gradients). Then, the suspensions were cooled to 27 and
17 °C to reach hypothermia conditions. Also, series of
the experiments were performed without abovemen-
tioned preliminary incubation of synaptosomes at 37 °C.
In these experiments, cold synaptosomes were warmed
up to 17, 27, and 37 °C. In both approaches, uptake was
started by the application of the mixture of L-glutamate
(10 μM) supplemented with L-[14C]glutamate (420 nM,
0.1 μCi/ml), synaptosome preparations were incubated
during 1 min, and then quickly sedimented at 10,000
g for 20 s using a microcentrifuge. L-[14C]glutamate
uptake by synaptosomes was calculated as a lowering
of radioactivity in aliquots of the supernatant (sample
volume of 100 μl) and a radioactivity augmentation in
the SDS-treated pellets. Amount of radioactivity was
detected using ACS scintillation cocktail (volume per
sample of 1.5 ml) and liquid scintillation counting
[21, 30, 31]. Data were collected from several inde-
pendent experiments performed in triplicate with dif-
ferent synaptosome preparations (n). Data were
presented as mean ± SEM.
Recording of L-[14C]glutamate release from nerve
terminals
Synaptosome preparations were diluted to 2 mg of pro-
tein per milliliter and after 10 min preincubation at 37 °
C were loaded with radiolabeled L-[14C]glutamate,
1 nmol/mg of protein, and 238 mCi/mmol in Ca2+-con-
taining media at 37 °C during 10 min. Then, the synap-
tosomes were washed with 10 volumes of ice-cold
standard salt solution; the pellets were collected and re-
suspended (final protein concentration of 1 mg/ml). The
synaptosome preparations (sample volume of 125 μl,
0.5 mg of protein/ml) were pre-incubated at 37 °C for
8 min (typical experimental procedure for restoration of
ionic gradients). After that, the synaptosome prepara-
tions were cooled to 27 and 17 °C to reach hypothermia
conditions. Also, series of experiments were performed
without abovementioned preliminary incubation at 37 °
C. In these experiments, cold synaptosomes were
warmed up to 17, 27, and 37 °C. Experiments on release
of L-[14C]glutamate were carried out in Ca2+-free incu-
bation media, where synaptosomes were incubated for
different time intervals 0–30 min and then rapidly sedi-
mented at 10,000 × g for 20 s in a microcentrifuge. Re-
lease was recorded in 100 μl of aliquots of the
supernatant and the SDS-treated pellets using scintilla-
tion cocktail ACS (volume per sample of 1.5 ml) and
liquid scintillation counting. Total L-[14C]glutamate
amount in the synaptosomes was 200,000 ± 15,000 cpm/
mg protein. For the assessment of tonic release of the
neurotransmitter, the synaptosomes were incubated
without stimulating agents. DL-TBOA and FCCP were
added to synaptosomes at 0-time point.
Statistical analysis
Results were presented as mean ± SEM of n independent
experiments. Statistical differences were confirmed by
two-tailed Student’s t test. Difference was considered sig-
nificant, when P ≤ 0.05.
Materials
HEPES, EGTA, EDTA, DL-TBOA, FCCP, Ficoll 400, and
analytical grade salts were purchased from Sigma (USA);
ACS—from Amersham (UK); radiolabelled L-[14C]gluta-
mate—from Amersham (UK) and PerkinElmer (USA).
Results
Rationale
The majority of the experimental methods usually ap-
plied for the analysis of key characteristics of glutamater-
gic neurotransmission cannot be used in hypothermia-
related studies because they are temperature-sensitive
per se. For example, measurements of the membrane
potential and synaptic vesicle acidification [32] using po-
tential- and pH-sensitive dyes, respectively, depend not
only on temperature-dependent changes in above char-
acteristics but also on the ability of the dye to penetrate
the hypothermia-affected plasma membrane etc. There-
fore, such experimental data can be incorrect or need
additional severe controls. The methodological ap-
proach, which allows to measure directly and adequately
temperature-dependent changes in presynaptic neuro-
transmitter transport, involves the use of radiolabelled
neurotransmitters.
The experiments on the analysis of hypothermia-
induced effects were subdivided in two groups. The first
one related to non-pathological processes in normal
nerve terminals, that is, assessment of the uptake, tonic
release, and the extracellular level of glutamate without
and in the presence of glutamate transporter inhibitor
DL-threo-β-benzyloxyaspartate (DL-TBOA) [33]. The
second one was associated with pathological ischemia-
related transporter-mediated glutamate release induced
by depolarization of the plasma membrane of nerve ter-
minals and dissipation of the proton gradient of synaptic
vesicles. This mechanism significantly contributes to the
development of excitotoxicity under hypoxia/ischemia
conditions.
The experiments were conducted in the suspension of
nerve terminals (synaptosomes) isolated from rat brain
cerebral hemispheres. They retain major characteristics
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of intact nerve terminals: (*) the ability to maintain the
membrane potential and the proton gradient of synaptic
vesicles, (**) accomplish uptake and transporter-
mediated release of glutamate, (***) exocytosis, etc. Syn-
aptosomes are considered as one of the best systems to
study presynaptic processes [34].
Analysis of the size of nerve terminals by dynamic light
scattering under conditions of deep and profound
hypothermia
The average diameter of the particles in the synapto-
some preparations was evaluated using dynamic light
scattering in order to assess whether or not deep/pro-
found hypothermia caused changes in the size of synap-
tosomes or their aggregation. As shown in Fig. 1, the
size of synaptosomes (protein concentration of 0.5 mg/
ml) was equal to 2.3 ± 0.3 μm in control at 37 °C, 2.4 ±
0.1 μm at 27 °C, and 2.3 ± 0.3 μm at 17 °C. Therefore,
significant changes were not found in the size of synap-
tosomes at 27 and 17 °C in comparison with 37 °C, and
so exposure of synaptosomes to above temperature con-
ditions did not cause their aggregation at the concentra-
tions used.
Discrimination of hypothermia-induced changes in non-
pathological mechanisms of glutamate transport in brain
nerve terminals
Tonic release of glutamate from nerve terminals under
conditions of deep and profound hypothermia
Definite level of extracellular glutamate is very important
for correct synaptic transmission, and appears to be
unique individual characteristic of each synapse [35]. It
is clear that temperature-induced changes in the extra-
cellular level of L-[14C]glutamate depend on a dynamic
balance of oppositely directed processes, that is, uptake
and release (see “Background” and “Discussion” sec-
tions). In the first set of the experiments, tonic glutam-
ate release from nerve terminals, i.e. one of the
abovementioned constituents determined the extracellu-
lar level of glutamate, was assessed. Analysis of tonic re-
lease of L-[14C]glutamate from synaptosomes revealed
that it decreased in conjunction with a reduction of
temperature and consisted of 3.9 ± 0.3 % of total synap-
tosomal label at 37 °C, 0.1 ± 0.08 % of total synaptosomal
label at 27 °C (P ≤ 0.001, Student’s t test, n = 20), and
0.74 ± 0.08% of total synaptosomal label at 17 °C (P ≤
0.001, Student’s t test, n = 20). Tonic release of L-
[14C]glutamate from synaptosome preparations was cal-
culated for 6 min, i.e., between 8- and 14-min time
points, starting from warming of synaptosomes from +4
to 17, 27, and 37 °C, and vice versa by cooling from 37
to 27 and 17 °C. Therefore, tonic release of L-[14C]glu-
tamate significantly decreased under conditions of
hypothermia, and unexpectedly, this decrease was more
considerable in deep than in profound hypothermia
(Fig. 2).
Transporter-mediated glutamate uptake by nerve terminals
under conditions of deep and profound hypothermia
As shown in Fig. 3, deep and profound hypothermia
caused significant changes in the initial velocity of L-
[14C]glutamate uptake by synaptosomes. The initial vel-
ocity of L-[14C]glutamate uptake by synaptosomes was
equal to 2.63 ± 0.08 nmol min−1 mg−1 protein at 37 °C,
decreased to 2.09 ± 0.2 nmol min−1 mg−1 protein at 27 °
C, and further decreased to 1.48 ± 0.12 nmol min−1 mg
−1 protein at 17 °C (P ≤ 0.05, Student’s t test, n = 6). Ac-
cumulation of L-[14C]glutamate by synaptosomes for
10 min consisted of 9.83 ± 0.35 nmol mg−1 protein at
37 °C, 7.42 ± 0.27 nmol min−1 protein at 27 °C, and 5.75
± 0.52 nmol mg−1 protein at 17 °C (P ≤ 0.05, Student’s t
test, n = 6). Therefore, deep and profound hypothermia
Fig. 1 Dynamic light scattering histograms. Synaptosomal
suspension (0.2 mg/ml) in a standard saline solution at 37 (a), 27 (b),
and 17° C (c)
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significantly inhibited L-[14C]glutamate uptake by
synaptosomes.
The extracellular level of glutamate in the preparations of
nerve terminals under conditions of deep and profound
hypothermia
As it was indicated in the previous sections, definite extra-
cellular glutamate concentration in nerve terminals is
maintained by oppositely directed processes, that is, uptake
and release. The extracellular level of L-[14C]glutamate in
the synaptosome preparations was measured at 14-min
time point after warming or cooling of synaptosomes (see
“Methods” section). To obtain representative experimental
data, more than 30 experiments with synaptosomal prepa-
rations isolated from different animals were performed that
were an order more than for usual measurements per par-
ameter (Fig. 4). It was calculated that in a half of the experi-
ments extracellular L-[14C]glutamate was decreased in
hypothermia (Fig. 5a), and in a half—it was increased
(Fig. 5b). Statistical analysis of the experimental data from
both groups revealed the absence of significance between
the control and hypothermia. This fact can be explained by
Fig. 2 Tonic release of L-[14C]glutamate from nerve terminals under conditions of deep and profound hypothermia. 37 (empty column), at 27 (grey
column), and 17 °C (black column). L-[14C]glutamate release was measured as described in the “Methods” section. Total synaptosomal L-[14C]glutamate
content was equal to 200,000 ± 15,000 cpm/mg protein. Data are means ± SEM of 30 independent experiments, each performed in triplicate. Data are
compared by Student’s t test. *, P≤ 0.001 as compared to synaptosomes at 37 °C; #, as compared to synaptosomes at 17 °C
Fig. 3 Time course of L-[14C]glutamate uptake by nerve terminals under conditions of deep and profound hypothermia. 37 (solid line), 27 (dash
line), and 17 °C (dotted line). L-[14C]glutamate uptake was measured as described in the “Methods” section
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the uniqueness of release/uptake balance established in
each synapse, which is determined by individual synaptic
characteristics such as the amount and distribution of glu-
tamate transporters, lipid composition of the plasma mem-
brane, and energetical status of nerve terminals. As a result,
in one animal, a decrease in uptake prevails on a decrease
in tonic release of L-[14C]glutamate and in other one vice
versa. As shown in Fig. 4, the average extracellular level of
L-[14C]glutamate was changed insignificantly as a result of a
decrease in the temperature. At 14-min time point after
warming/cooling of cold/warm synaptosomes, it consisted
of 280 ± 28 pmol/mg of protein at 37 °C, 212 ± 23 pmol/mg
of protein at 27 °C, and 241 ± 23 pmol/mg of protein at
17 °C (n = 30) (Fig. 4). Therefore, it was concluded that in
comparison to significantly inhibited uptake and tonic re-
lease of L-[14C]glutamate, the extracellular L-[14C]glutamate
level was changed insignificantly under deep/profound
hypothermia. The only explanation of this fact is that tonic
release decreased with comparable effectiveness with L-
[14C]glutamate uptake, and so lowering of L-[14C]glutamate
leakage competed with weakness of uptake.
The next set of the experiments was performed for as-
sessment of hypothermia-induced changes in the value of
the extracellular level of L-[14C]glutamate in the suspension
of nerve terminals during blockage of glutamate transporter
functioning by competitive non-transportable inhibitor
of glutamate transporters DL-threo-β-benzyloxyaspartate
(DL-TBOA) [33]. The extracellular level of L-[14C]glutamate
in synaptosome preparations significantly decreased in
deep/profound hypothermia under conditions of inhibition
of glutamate uptake. No significant difference in extracellu-
lar L-[14C]glutamate in synaptosome preparations in the
presence of glutamate transporter blocker was revealed
between deep and profound hypothermia.
Discrimination of hypothermia-induced changes in patho-
logical ischemia-related mechanisms of glutamate trans-
port in brain nerve terminals
Stimulated by depolarization of the plasma membrane
transporter-mediated release of glutamate from nerve ter-
minals under conditions of deep and profound hypothermia
In hypoxia, ischemia, stroke, brain trauma, hypoglycemia,
etc, an increase in the extracellular glutamate level causes
neurotoxicity and neuronal death. Transporter-mediated
glutamate release is the main mechanism that leads to an
augmentation of the extracellular glutamate concentration
under these pathological conditions. Depolarization of the
plasma membrane of nerve terminals by high KCl in Ca2
+-free medium causes reversal of glutamate transporters
and transporter-mediated release of glutamate from the
cytosol. It was shown that stimulation by high KCl release
of L-[14C]glutamate decreased in a progressive way under
conditions of deep and profound hypothermia. The value
of this release measured at 6-min time point was equal to
12 ± 1% of total accumulated label at 37 °C, 10.0 ± 0.5% of
total accumulated label at 27 °C, and 6.0 ± 0.5% of total
accumulated label at 17 °C (P ≤ 0.05, Student’s t test, n = 5)
(Fig. 6). Therefore, data on depolarization-evoked
transporter-mediated release of L-[14C]glutamate from
synaptosomes showed that the velocity of this release was
decreased gradually from deep to profound hypothermia.
Protonophore-induced glutamate release from nerve
terminals under conditions of deep and profound
hypothermia
The protonophore FCCP is used in the experiments due
to its ability to dissipate the proton gradient of synaptic
vesicles and inhibit glutamate uptake [27]. These condi-
tions favor an augmentation of transporter-mediated L-
Fig. 4 The extracellular level of L-[14C]glutamate in the synaptosomal suspension under conditions of deep and profound hypothermia. The level was
measured at 14-min time point (see the “Methods” section) at 37 (empty column), 27 (grey column), and 17 °C (black column). Total synaptosomal L-[14C]glu-
tamate content was equal to 200,000 ± 15,000 cpm/mg protein. Data are means ± SEM of 30 independent experiments, each performed in triplicate
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[14C]glutamate release from synaptosomes. FCCP-
evoked L-[14C]glutamate release from synaptosomes was
significantly inhibited by the transporter inhibitor DL-
TBOA, so this release was mediated by glutamate trans-
porters. In this set of the experiments, the effect of deep
and profound hypothermia on L-[14C]glutamate release
from synaptosomes during application of FCCP was ana-
lyzed. As shown in Fig. 7, FCCP-evoked release of L-
[14C]glutamate for 6 min was equal to 15.5 ± 1.0% of total
accumulated label at 37 °C, 9.5 ± 1.0% of total accumulated
label at 27 °C (P ≤ 0.05, Student’s t test, n = 4), and 6.3 ±
0.5% of total accumulated label at 17 °C (P ≤ 0.05, Student’s
t test, n = 4).
Discussion
Glutamate-related mechanism of neuroprotective ac-
tion of hypothermia is still debated despite a lot of
experimental data [7, 10, 18, 19, 36]. The explanation
of the possible neuroprotective effect of lowering
body temperature in acute stroke remains largely
speculative [9]. However, most studies point toward
lowering down of the neurodegenerative processes in
the penumbra [18, 19, 37, 38]. Also, there are no
clear standards of the parameters in therapeutic
hypothermia [13], and the optimal temperature for




Fig. 5 Two groups of animals with different changes in the extracellular level of L-[14C]glutamate in the synaptosomal suspension under
conditions of deep and profound hypothermia. The experiments were subdivided in two groups with a tendency to decrease (a) and increase (b)
in the value of extracellular L-[14C]glutamate in the synaptosomal suspension in hypothermia. The level was measured at 14-min time point (see
the “Methods” section) at 37 (empty columns), 27 (grey columns), and 17 °C (black columns). Total synaptosomal L-[14C]glutamate content was
equal to 200,000 ± 15,000 cpm/mg protein. Data are means ± SEM of 30 independent experiments, each performed in triplicate
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In this study, double discrimination of the effects of
deep and profound hypothermia (the first type of dis-
crimination) on non-pathological and pathological
mechanisms (the second type of discrimination) of pre-
synaptic L-[14C]glutamate transport was performed using
rat brain nerve terminals. According to the recent hy-
pothesis forwarded by the author of this study, a definite
and non-negligible concentration of extracellular glu-
tamate between the episodes of exocytotic release is
established mainly by permanent transporter-mediated
glutamate turnover across the plasma membrane of
nerve terminals with a contribution of non-transporter
tonic glutamate release by spontaneous exocytosis, diffu-
sion, cystine-glutamate exchanger, and leakage through
anion channels [15]. Nevertheless, glutamate transporter
reversal remains the major mechanism of glutamate re-
lease under energy deprivation conditions, in hypoxia,
hypoglycemia, brain trauma, stroke, underlying augmen-
tation of the extracellular glutamate concentration, and
development of excitotoxicity. Dynamics of L-[14C]glu-
tamate turnover (between episodes of exocytosis) and its
constitutive mechanisms, that is, high-affinity Na
+-dependent uptake accompanied with non-pathological
transporter-mediated release of L-[14C]glutamate, and
Fig. 6 Stimulated by high KCl (35 mM) transporter-mediated release of L-[14C]glutamate from nerve terminals under conditions of deep and profound
hypothermia. Release was measured at 37 (empty columns), 27 (grey columns), and 17 °C (black columns). L-[14C]glutamate release was measured as
described in the “Methods” section, and L-[14C]glutamate radioactivity was determined at 6-min time point. Data are means ± SEM of five independent
experiments, each performed in triplicate. *, P≤ 0.05 as compared to the control
Fig. 7 Transporter-mediated release of L-[14C]glutamate from nerve terminals in the presence of the protonophore FCCP (1 μM) under conditions
of deep and profound hypothermia. L-[14C]glutamate release was measured as described in the “Methods” section, and L-[14C]glutamate
radioactivity was determined at 6-min time point. 37 (empty columns), 27 (grey columns), and 17 °C (black columns). Data are means ± SEM of four
independent experiments, each performed in triplicate. *, P ≤ 0.05 as compared to control
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also tonic L-[14C]glutamate release, were analyzed separ-
ately under conditions of deep and profound hypothermia.
A balance of hyperthermia-induced changes in above con-
stituents determines definite extracellular level of L-
[14C]glutamate in nerve terminals under experimental con-
ditions. It was shown that transporter-mediated L-[14C]glu-
tamate uptake was decreased in progressive manner from
deep to profound hypothermia (Fig. 3). Theoretical calcula-
tions predict that non-pathological glutamate transporter
reversal (as a component of permanent transporter-
mediated turnover) should also decrease under
hypothermia. Unfortunately, this component cannot be
measured directly by any methodological approaches.
Tonic release of L-[14C]glutamate for 6 min de-
creased more considerably (almost completely absent)
under conditions of deep hypothermia (Fig. 2, the
second column) in comparison with profound one
(Fig. 2, the third column). It was clearly demonstrated
that no gradual decrease in tonic L-[14C]glutamate re-
lease between deep and profound hypothermia was
registered. Summarizing, uptake of L-[14C]glutamate
decreased progressively (Fig. 3), whereas tonic release
decreased almost similarly in deep to profound
hypothermia by more than 80% (Fig. 2).
Theoretical calculations predict that if transporter-
mediated L-[14C]glutamate uptake is more sensitive to
deep and profound hypothermia than the sum of non-
pathological transporter-mediated and non-transporter
tonic release of L-[14C]glutamate, the extracellular level
of L-[14C]glutamate should increase in the preparation of
nerve terminals and vice versa if release is more sensiti-
ve—this level should decrease. Taking ten times more
animals than for ordinary series of the experiments, it
was shown that the ability to maintain the balance gluta-
matein/glutamateout in hypothermia, and so extracellular
level of L-[14C]glutamate was individual for each animal.
It is so because in 50% of experiments, the extracellular
L-[14C]glutamate level was decreased under hypothermia
(Fig. 5a) and in 50%—it was increased (Fig. 5b). As a re-
sult, the statistic calculation showed the absence of sig-
nificance in hypothermia-dependent decrease in the
extracellular level of L-[14C]glutamate in the preparation
of nerve terminals (Fig. 4).
Absence of significant changes in extracellular L-
[14C]glutamate in the preparation of nerve terminals
despite of reduced L-[14C]glutamate uptake during low-
ering of temperature is valuable per se. It is clear from
these hypothermia experiments that release components
(tonic and non-pathological transporter reversal) have
significant contribution to the establishment and main-
tenance of proper extracellular glutamate concentration.
Variability of hypothermia-induced changes in extracel-
lular L-[14C]glutamate shown in this study favors our re-
cent suggestion regarding individuality and uniqueness
of the extracellular level of the neurotransmitters for
each synapse [35].
Therefore, the effect of therapeutic hypothermia on
the extracellular level of glutamate in nerve terminals
unaffected by hypoxia/ischemia cannot be predicted a
priori. Taking into account the above fact, it is clear that
the changes in the extracellular level of glutamate during
hypothermia are unique for each patient, and so the in-
dividual approach of the evaluation of hypothermia pa-
rameters should be developed.
Our data coincides with the results of Boris–Moller
and Wieloch [39], who found an attenuation of glutam-
ate levels only in the striatum, whereas cortical ones, al-
though were lower at the baseline, but were not
attenuated by hypothermia. However, the experimental
data is not in accord with microdialysis measurements
that demonstrated that glutamate dialysate concentra-
tions in non-infarcted brain tissue decreased from 3.6 to
2.6 mol/L in mild hypothermia [10]. Only a tendency to
decrease in synaptosomal extracellular L-[14C]glutamate
was found in our experiments.
This study also focused on the analysis of the velocity
of pathological glutamate transporter reversal induced
by membrane depolarization and FCCP that reflected
hypothermia-induced changes in ischemia-injured nerve
terminals. Development of neurotoxicity in stroke, cere-
bral hypoxia, and ischemia, cardio surgery with circula-
tion arrest, and traumatic brain injury is provoked by
excessive extracellular glutamate mainly originated from
glutamate transporter reversal. Glutamate transporter
reversal was stimulated by depolarization of the plasma
membrane by 35 mM KCl (Fig. 6) and by dissipation of
the proton gradient of synaptic vesicles with the proto-
nophore FCCP (Fig. 7), and a gradual decrease from
deep to profound hypothermia in the velocity of
transporter-mediated L-[14C]glutamate release from syn-
aptosomes was shown. This fact indicates a progressive
neuroprotective effect increased from deep to profound
hypothermia in affected by hypoxia/ischemia zones, e.g.,
in core and penumbra zones of the insult. This experi-
mental data coincides with the results of [40], where the
authors analyzing the dialysate concentrations showed
that the rate of an ischemia-induced increase in glutam-
ate concentration was inhibited by low temperature, and
was equal to 58.4 ± 31.8 μmol/L at 38 °C to 15.9 ±
8.4 μmol/L at 25 °C. Also, our results agree with those
of Berger [10], where the authors demonstrated using
microdialysis measurements that glutamate dialysate
concentrations in peri-infarct tissue were significantly
influenced by hypothermia (extracellular glutamate, 4.8
versus 12.6 mol/L). In this context, we partially agree
with the suggestion that hypothermia exerts a neuropro-
tective effect by extracellular glutamate attenuation in
penumbral regions and possibly within the infarct core.
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The present study brings new insight to the above state-
ment, namely, it is true, when the nerve cells are still
able to release glutamate by transporter reversal (Figs. 6
and 7) and also by non-transporter mechanisms (Fig. 2).
In considerably injured nerve cells, the above mecha-
nisms do not work because of thermodynamic reasons,
i.e., reduction of the glutamatein/glutamateout gradient
across the plasma membrane. In this context, selection
of optimal individual temperature regime for patients in
dependence of the size of irreversibly injured zone and
extent of penumbra one is of value.
Taking into account abovementioned facts, it is sug-
gested that the strategy of successful therapeutic
hypothermia from one side is a reduction of its possible
harmful effects on hypoxia/ischemia-unaffected nerve
cells by stabilization of the extracellular glutamate con-
centration through the balancing release/uptake constit-
uents. It is rational to make hypothermia-induced
decrease in glutamate transporter reversal more signifi-
cant, thereby enhancing its direct neuroprotective effect.
Above recommendations can be realized by combination
of unspecific effects of hypothermia with other unspe-
cific and specific neuroprotectants.
In medical practice, there are no specific agents for
modulation of glutamate transporter activity, in contrast
to selective inhibitors of GAT1 and GAT3 GABA trans-
porters, tiagabine, and β-alanine, respectively. In this
context, unspecific modulation of transporter activity is
the only available approach to decrease significantly
pathological transporter-mediated glutamate release
from nerve terminals. Unspecific neuroprotection can be
performed by hypothermia and also by temporal choles-
terol deficiency. Recently, we have shown that a decrease
in the level of membrane cholesterol in nerve terminals
reduced pathological transporter-mediated glutamate re-
lease. These data can explain the neuroprotective effect
followed by the administration of statins in excitotoxi-
city, stroke, cerebral hypoxia and ischemia, seizures, oxi-
dative damage, and traumatic brain injury. However, we
underline that except abovementioned pathologies, the
normal levels of membrane cholesterol are extremely
important for correct synaptic transmission and a de-
crease in membrane cholesterol content of nerve termi-
nals may cause neurotoxic consequences because of
weak glutamate uptake and the enlargement of the
extracellular glutamate concentration [32, 41, 42]. Also,
nanoparticles can be perspective for modulation of glu-
tamate transport and visualization of key processes in
nerve terminals [43].
Limitations of the study
The main limitation of this study is associated with the
fact that data was obtained from in vitro experiments.
Nevertheless, the existence of pathological glutamate
transporter reversal and importance of the extracellular
glutamate level is commonly accepted [10, 14, 16].
Recommendations for PPPM
The results of this study are of value for PPPM, a medi-
cine that focuses on the combined diagnosis, prevention,
and treatment of disease in individual patients. Discrim-
ination of hypothermia-induced changes in non-
pathological and pathological glutamate transport in
nerve terminals, proven diversity of above hypothermia-
induced effects, and individuality of changes in extracel-
lular glutamate underscores usefulness of the result im-
plementation in PPPM. It is suggested from our study
that the neurological complications in cardiac surgery
can be associated with an increase extracellular glutam-
ate level. In “healthy” nerve terminals, hypothermia-
induced changes in the extracellular glutamate level can-
not be predicted because hypothermia sensitivity of up-
take vs. tonic release cannot be assessed by known
approaches. However, blood platelets are able to accom-
plish glutamate uptake by neuronal-like high-affinity Na
+-dependent glutamate transporters EAAT 1-3 of the
plasma membrane [35]. This feature of platelets may be
used for characterization of hypothermia sensitivity of
glutamate transport in brain nerve terminals. Similarities
of platelets with nerve terminals underlie possible usage
of platelets as a model of glutamate transport in the pre-
synapse and an analytic, diagnostic, and prognostic bio-
marker for the analysis of the alterations in the
functioning of glutamate transporters in the brain [35].
Interrelation between changes in glutamate transport
and metabolism in the brain and platelets was shown
[44–47], and so the possible role of platelets as a diag-
nostic and prognostic marker in various neurodegenera-
tive diseases was suggested [48]. The probable
physiological role of platelets in extracellular glutamate
homeostasis in the central nervous system is realized by
removing of excessive extracellular glutamate [49–52].
The importance of proper glutamate concentration in
the blood was demonstrated in [53].
Taking into account our data on significant gradual
decrease in pathological glutamate transporter reversal,
it is clear that the more size of penumbra zone, the less
temperature in therapeutic hypothermia should be ap-
plied. Preliminary diagnostics and neuromonitoring
should be an essential part of hypothermia therapy help-
ing physicians to choose optimal temperature regime.
Increased plasma glutamate in stroke patients was regis-
tered [48]. In this context, non-neuronal glutamate can
serve as a diagnostic, prognostic, and predictive bio-
marker, and glutamate biosensor [31] can be applied in
medical practice. In contrast, platelets cannot be in-
cluded in neuromonitoring of pathological glutamate
transporter reversal, because we recently showed that
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this manner of glutamate release in platelets is rather
ambiguous [35] and glutamate is released from platelets
exclusively by means of exocytosis.
Therefore, the PPPM goal for the future is to imple-
ment comprehensive neuromonitoring of glutamate-
related parameters in the blood plasma, platelets, and
cerebrospinal liquids that helps to select optimal individ-
ual temperature regime for patients with prescribed
therapeutic hypothermia (Fig. 8). Validation of proposed
biomarkers, i.e., glutamate concentration in the blood
and cerebrospinal liquids and glutamate transport char-
acteristics of platelets, is necessary before their incorpor-
ation into standard clinical decision-making algorithms.
Personalized approach will certainly play the crucial role
in the more effective and better tailored hypothermia
treatment in cardiac surgery of the aortic arch and in is-
chemic stroke.
In perspective, we plan to develop the panels of
glutamate-related biomarkers for neuromonitoring of
the patients reflected individual hypothermia-induced ef-
fects in nerve terminals that will serve for the outcome
prediction methodology. This plan bases on our recent
results that the extracellular glutamate level is unique
for each synapse [35], a possibility to analyze kinetics of
glutamate uptake by nerve terminals using glutamate
biosensor [31], and characteristic features of glutamate
Fig. 8 Roadmap of the study
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transport in blood platelets [35]. These data can be proc-
essed in appropriate way and be a base for development
of new computational and mathematical tools to predict
hypothermia effects.
Conclusions
Summarizing, dual discrimination of the effects of deep
and profound hypothermia on non-pathological and
pathological mechanisms of presynaptic glutamate trans-
port was performed using rat brain nerve terminals.
Hypothermia-induced changes in extracellular L-
[14C]glutamate in unaffected ischemia nerve terminals
are not evident. It is so because the differently directed
constituents determined physiological extracellular level,
that is, glutamate uptake and tonic release both were de-
creased in deep and profound hypothermia.
Therefore, in unaffected nerve terminals, the direction
of changes in extracellular glutamate in deep and pro-
found hypothermia is unpredictable and depends on in-
dividual synaptic characteristics. While in affected ones
(e.g., in brain regions suffering from a reduction of blood
circulation during cardio surgery and core and penum-
bra zones of the insult), pathological transporter-
mediated glutamate release decreased with progressive
significance from deep to profound hypothermia,
thereby underlying its unspecific potent neuroprotective
effect in stroke, hypoxia and ischemia, cardiac surgery
with application of circulation arrest, and traumatic
brain injury, where excitotoxicity progress is associated
with an increase in glutamate uptake reversal. Our data
revealed the necessity of development and advance of
special parameters in PPPM for individual neuromoni-
toring in hypothermia.
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